previous
recombin
vesicular
stomat
viru
rvsv
pseudotyp
express
ebolaviru
glycoprotein
gp
place
vsv
g
protein
demonstr
protect
nonhuman
primat
lethal
homolog
ebolaviru
challeng
pseudotyp
vector
contain
addit
attenu
mutat
rvsv
genom
describ
rvsv
vector
contain
full
complement
vsv
gene
express
ebola
viru
ebov
gp
addit
transcript
unit
rvsv
vector
contain
combin
attenu
mutat
use
previous
clinic
develop
pathway
rvsvhuman
immunodefici
viru
type
vaccin
one
rvsv
vector
express
membraneanchor
ebov
gp
first
posit
genom
elicit
balanc
cellular
humor
gpspecif
immun
respons
mice
guinea
pig
immun
singl
dose
vector
protect
sign
diseas
follow
lethal
ebov
challeng
control
anim
die
day
subsequ
demonstr
complet
singledos
protect
macaqu
follow
lethal
ebov
challeng
singl
shamvaccin
macaqu
die
diseas
due
ebov
infect
result
demonstr
highli
attenu
rvsv
vector
express
ebov
gp
may
provid
safer
altern
current
ebov
vaccin
previous
recombin
vesicular
stomat
viru
rvsv
pseudotyp
express
ebolaviru
glycoprotein
gp
place
vsv
g
protein
demonstr
protect
nonhuman
primat
lethal
homolog
ebolaviru
challeng
pseudotyp
vector
contain
addit
attenu
mutat
rvsv
genom
describ
rvsv
vector
contain
full
complement
vsv
gene
express
ebola
viru
ebov
gp
addit
transcript
unit
rvsv
vector
contain
combin
attenu
mutat
use
previous
clinic
develop
pathway
rvsvhuman
immunodefici
viru
type
vaccin
one
rvsv
vector
express
membraneanchor
ebov
gp
first
posit
genom
elicit
balanc
cellular
humor
gpspecif
immun
respons
mice
guinea
pig
immun
singl
dose
vector
protect
sign
diseas
follow
lethal
ebov
challeng
control
anim
die
day
subsequ
demonstr
complet
singledos
protect
macaqu
follow
lethal
ebov
challeng
singl
shamvaccin
macaqu
die
diseas
due
ebov
infect
result
demonstr
highli
attenu
rvsv
vector
express
ebov
gp
may
provid
safer
altern
current
ebov
vaccin
keyword
attenu
rvsv
vector
ebola
vaccin
glycoprotein
challeng
nonhuman
primat
genu
ebolaviru
classifi
within
filovirida
famili
compris
close
relat
antigen
distinct
viru
speci
bundibugyo
ebolaviru
reston
ebolaviru
sudan
ebolaviru
tai
forest
ebolaviru
zair
ebolaviru
natur
reston
viru
isol
subsaharan
africa
like
viru
reservoir
thought
bat
tai
forest
reston
virus
caus
sporad
deadli
outbreak
diseas
human
sinc
discoveri
ebolaviru
year
ago
casefat
rate
ongo
ebola
viru
ebov
outbreak
west
africa
largest
record
casefat
rate
around
hospit
patient
seemingli
improv
clinic
outcom
public
health
initi
may
slow
spread
diseas
mass
vaccin
program
ebovendem
region
like
requir
extinguish
current
outbreak
prevent
occurr
futur
ebov
genom
compos
singl
strand
negativesens
rna
approxim
kb
length
encod
major
viral
polypeptid
one
protein
ebov
glycoprotein
ebovgp
mediat
virion
attach
fusion
suscept
cell
ebovgp
also
contain
major
viru
neutral
epitop
accordingli
ebovgp
target
varieti
ebov
vaccin
design
thorough
review
vaccin
approach
see
falzarano
et
al
vector
one
vaccin
recombin
vesicular
stomat
viru
rvsv
gene
encod
vsv
g
replac
gene
encod
ebovgp
rvsv
pseudotyp
replic
effici
cell
cultur
also
propag
vivo
vsv
member
rhabdovirida
famili
similar
ebov
singlestrand
negativesens
rna
genom
approxim
kb
long
encod
major
viral
protein
natur
vsv
cycl
bite
insect
like
reservoir
livestock
viru
replic
high
titer
virusinduc
vesicl
insect
bite
site
nose
lip
teat
coronari
band
hoov
diseas
livestock
selflimit
typic
resolv
day
without
signific
consequ
vsv
also
infect
human
close
contact
infect
anim
purifi
viru
infect
result
mild
influenzalik
symptom
typic
resolv
day
without
complic
low
seropreval
vsv
human
favor
develop
vsv
vaccin
vector
becam
feasibl
rose
et
al
develop
system
recoveri
rvsv
genom
complementari
dna
cdna
sinc
rvsv
vector
express
antigen
human
pathogen
demonstr
high
level
efficaci
respect
anim
diseas
model
vsv
exhibit
pronounc
gradient
gene
express
due
discontinu
messeng
rna
mrna
transcript
across
intergen
region
allow
modul
viru
protein
foreign
antigen
express
function
gene
distanc
transcript
promot
highli
attenu
rvsv
vector
express
human
immunodefici
viru
type
hiv
gag
first
posit
genom
develop
demonstr
safe
stringent
mous
nonhuman
primat
nhp
neurovirul
biodistribut
studi
rvsv
vector
attenu
combin
n
gene
transloc
posit
genom
truncat
g
protein
cytoplasm
tail
ct
amino
acid
aa
nativ
form
aa
vector
subsequ
shown
safe
immunogen
phase
clinic
trial
hvtn
hvtn
avail
http
clinicaltri
gov
vaccin
viremia
undetect
vsv
infect
assay
vsvspecif
polymeras
chain
reaction
assay
blood
urin
saliva
specimen
obtain
trial
particip
unpublish
data
describ
gener
attenu
rvsv
vector
express
ebovgp
immunogen
mice
vector
elicit
balanc
ebovgpspecif
humor
cellular
immun
respons
mice
evalu
protect
efficaci
guinea
pig
nhp
challeng
studi
murin
studi
femal
balbc
mice
use
mice
maintain
accord
guid
care
use
laboratori
anim
addit
procedur
use
care
mice
approv
profectu
bioscienc
new
york
medic
colleg
institut
anim
care
use
committe
iacuc
guinea
pig
macaqu
studi
carri
strict
accord
recommend
describ
guid
care
use
laboratori
anim
nation
institut
health
offic
anim
welfar
us
depart
agricultur
anim
work
approv
nation
institut
allergi
infecti
diseas
divis
intramur
research
iacuc
rocki
mountain
laboratori
rml
facil
accredit
american
associ
accredit
laboratori
anim
care
procedur
perform
anim
anesthet
train
personnel
supervis
veterinari
staff
effort
made
minim
pain
suffer
anim
earli
end
point
criteria
specifi
rml
iacucapprov
score
paramet
use
determin
anim
human
euthan
describ
previous
vector
use
templat
gener
rvsvebov
vector
express
ebovgp
genom
cdna
modifi
exchang
gag
gene
locat
posit
genom
ebovgp
gene
mayinga
isol
gener
cdna
figur
vector
express
thirdposit
ebovgp
figur
gener
insert
express
cassett
n
gene
insert
ebovgp
gene
genom
posit
figur
n
g
gene
swap
express
cassett
posit
vsv
l
trailer
sequenc
adventiti
agent
test
clinic
trial
materi
larg
quantiti
ebovgpspecif
neutral
antibodi
requir
neutral
vaccin
viru
infect
avoid
requir
gene
express
secret
ebovgp
gener
delet
sequenc
encod
transmembran
region
cytoplasm
tail
aa
modifi
ebovgp
gene
insert
posit
figur
mucinlik
domain
ebovgp
span
aa
part
domain
aa
delet
figur
modifi
ebovgp
gene
gener
follow
observ
part
mucin
region
delet
upon
multipl
serial
passag
vero
cell
monolay
includ
assess
effect
partial
remov
glycan
coat
ebovgp
immunogen
ebovgp
express
analyz
western
blot
vector
figur
vector
rescu
genom
cdna
previous
describ
rescu
viru
plaqu
purifi
amplifi
vero
cell
monolay
atcc
anim
studi
vector
purifi
infect
cell
supernat
centrifug
sucros
cushion
viru
pellet
resuspend
phosphatebuff
salin
pb
ph
mix
stabil
mm
k
hpo
mm
kh
po
mm
sucros
snap
frozen
store
mous
immunogen
studi
rvsvebov
vector
administ
plaqueform
unit
pfu
intramuscular
inject
tibiali
anterior
muscl
total
inject
volum
ml
serum
collect
week
ten
day
final
inocul
mice
euthan
co
inhal
serum
spleen
cell
harvest
mous
neurovirul
studi
group
ten
femal
swiss
webster
mice
anesthet
inocul
intracrani
ml
serial
dilut
vector
previous
describ
inocul
mice
weigh
daili
assess
sign
diseas
week
neurovirul
assess
measur
morbid
mortal
end
point
mice
show
sever
sign
diseas
moribund
promptli
euthan
cumul
death
across
dose
test
allow
lethal
dose
calcul
vector
guinea
pig
immun
pfu
vector
administ
intraperiton
day
vaccin
guinea
pig
challeng
focusform
unit
ffu
guinea
pigadapt
ebov
gpaebov
intraperiton
inject
anim
weigh
daili
monitor
sign
ill
macaqu
challeng
healthi
ebovna
adult
age
year
weight
kg
male
femal
rhesu
macaqu
macaca
mulatta
randomli
assign
vaccin
group
n
nonvaccin
control
group
n
studi
day
macaqu
anesthet
ketamin
inocul
caudal
thigh
muscl
pfu
rvsvebov
vector
total
volum
ml
studi
day
macaqu
anesthet
ketamin
challeng
ffu
ebov
intramuscular
inject
caudal
thigh
muscl
total
volum
ml
macaqu
monitor
sign
ill
ie
abnorm
temperatur
weight
loss
clinic
examin
find
hematolog
find
blood
chemistri
find
follow
vaccin
ebov
challeng
portion
studi
murin
studi
vaccineelicit
elispot
respons
determin
use
mous
elispot
kit
bd
bioscienc
san
diego
california
previous
describ
splenocyt
incub
cona
sigma
peptid
pool
overlap
aa
final
peptid
concentr
span
ebovgp
medium
alon
murin
enzymelink
immunosorb
assay
elisa
previous
describ
modifi
use
elisa
plate
coat
ngwell
purifi
recombin
ebovgp
ibt
bioservic
determin
ebovgpspecif
serum
immunoglobulin
g
igg
titer
murin
serum
sampl
ad
elisa
plate
start
dilut
dilut
across
plate
antigenspecif
antibodi
titer
defin
reciproc
last
serum
dilut
give
od
antigen
macaqu
elisa
produc
previous
describ
macaqu
sera
inactiv
mrad
accord
standard
oper
protocol
approv
institut
biosafeti
committe
rml
elisa
perform
describ
previous
identifi
mosteffect
rvsvebov
vector
design
induct
ebovgpspecif
immun
respons
vector
outlin
figur
compar
abil
elicit
ebovgpspecif
cellmedi
immun
bind
antibodi
respons
mice
figur
group
balbc
mice
n
immun
intramuscularli
studi
week
figur
ten
day
primari
immun
splenocyt
collect
micegroup
test
ebovgpspecif
secret
elispot
assay
remain
mice
group
boost
intramuscularli
studi
week
pfu
rvsvebov
vector
ten
day
boost
splenocyt
collect
test
describ
immun
highest
mean
ebovgpspecif
elispot
respons
error
mean
sem
detect
mice
immun
spotform
cell
sfc
splenocyt
splenocyt
interestingli
elicit
significantli
reduc
respons
mean
sem
splenocyt
rel
notabl
immun
gp
respons
undetect
mice
immun
vector
express
ebovgp
genom
posit
boost
highest
mean
ebovgpspecif
elispot
respons
detect
mice
immun
splenocyt
mean
sem
splenocyt
mice
immun
show
improv
respons
mean
sem
sfc
splenocyt
mice
boost
still
fail
demonstr
measur
ebovgpspecif
elispot
respons
immun
mice
also
monitor
induct
serum
antibodi
respons
elisa
figur
ten
day
boost
mean
serum
ebovgpspecif
igg
titer
highest
mice
immun
vector
interestingli
statist
signific
approxim
lower
ebovgpspecif
igg
titer
detect
mice
immun
mean
sem
rel
mice
immun
lower
titer
also
detect
mice
immun
rel
mice
immun
vector
express
ebovgp
genom
posit
basi
data
present
figur
vector
express
anchor
fulllength
ebovgp
posit
rvsv
genom
appear
immunogen
regard
cellmedi
humor
immun
mice
select
guinea
pig
nhp
challeng
studi
next
test
whether
could
protect
guinea
pig
lethal
challeng
figur
experi
guinea
pig
immun
intraperiton
pfu
control
addit
group
guinea
pig
immun
pfu
wtvsv
medium
alon
day
immun
guinea
pig
challeng
intraperiton
ffu
gpaebov
challeng
guinea
pig
monitor
chang
bodi
weight
figur
sign
diseas
surviv
figur
guinea
pig
immun
medium
alon
wtvsv
began
lose
weight
day
challeng
die
ebov
infect
studi
day
observ
previous
contrast
immun
guinea
pig
gain
weight
complet
protect
diseas
cours
studi
encourag
find
guinea
pig
studi
determin
whether
could
protect
macaqu
lethal
ebov
challeng
tabl
three
rhesu
macaqu
immun
intramuscularli
caudal
thigh
muscl
follow
immun
pfu
total
volum
ml
macaqu
ctrl
mock
immun
day
immun
macaqu
demonstr
measur
ebovgpspecif
serum
igg
respons
titer
respons
increas
titer
studi
day
contrast
shamimmun
macaqu
remain
seroneg
ebovgp
studi
day
macaqu
challeng
ffu
ebov
mayinga
intramuscular
inject
caudal
thigh
muscl
shown
tabl
singl
control
anim
fail
mount
ebovgpspecif
respons
day
challeng
quickli
die
ebov
infect
importantli
rapid
increas
ebovgpspecif
serum
igg
titer
observ
day
challeng
vaccin
macaqu
surviv
without
show
sign
diseas
mice
exquisit
sensit
intracrani
instil
wtvsv
lead
lethal
viral
enceph
previous
shown
intracrani
inocul
swiss
webster
mice
pfu
highli
attenu
vector
caus
signific
ill
lethal
dose
could
achiev
vector
test
neurovirul
potenti
group
outbr
swiss
webster
mice
inocul
intracrani
doserang
studi
pfu
figur
two
control
group
inocul
pfu
less
attenu
rvsv
pb
alon
follow
inocul
mice
assess
morbid
mortal
week
consist
previous
publish
report
mice
inocul
intracrani
pb
surviv
approxim
half
mice
inocul
die
day
inocul
importantli
mice
inocul
surviv
diseas
free
previou
work
demonstr
vaccin
singl
dose
replicationcompet
rvsv
pseudotyp
ebovgp
protect
mice
hamster
guinea
pig
nhp
lethal
ebov
challeng
rvsv
vector
use
studi
retain
natur
vsv
genom
organ
except
vsv
g
gene
replac
ebovgp
gene
demonstr
protect
guinea
pig
nhp
highli
attenu
replic
compet
form
rvsv
retain
vsv
g
gene
express
ebovgp
addit
transcript
unit
insert
posit
rvsv
genom
mous
immunogen
studi
demonstr
ebovgpspecif
cellmedi
immun
respons
robust
ebovgp
gene
first
posit
genom
compar
third
sixth
posit
consist
greater
rel
abund
ebovgp
infect
cell
due
steep
transcript
gradient
present
vsv
replic
cellmedi
immun
respons
similar
secret
anchor
form
ebovgp
indic
form
ebovgp
underw
similar
degre
process
present
tcell
epitop
antigenpres
cell
interestingli
signific
reduct
cellmedi
immun
respons
ebovgp
part
mucinrich
region
delet
possibl
result
alter
proteosom
process
ebovgp
direct
delet
tcell
epitop
decay
primari
cellmedi
immun
respons
second
vaccin
dose
boost
elispot
respons
level
seen
primari
vaccin
howev
still
detect
cellmedi
immun
respons
elicit
vector
express
ebovgp
posit
indic
requir
higher
ebovgp
level
infect
cell
gener
detect
ebovgpspecif
cellmedi
immun
respons
expect
ebovgpspecif
igg
respons
mice
greatest
vector
express
highest
level
ebovgp
genom
posit
interestingli
elicit
much
lower
level
ebovgpspecif
igg
specul
may
reflect
differ
tertiari
quaternari
structur
secret
ebovgp
compar
trimer
conform
achiev
anchor
ebovgp
notabl
secret
ebovgp
describ
differ
natur
occur
secret
form
ebovgp
translat
unedit
ebovgp
mrna
corollari
anchor
trimer
ebovgp
spike
surfac
infect
cell
viru
particl
present
dens
array
structur
epitop
may
interact
effici
b
cell
solubl
secret
ebovgp
case
particul
antigen
composit
ebovgpspecif
igg
respons
highest
possibl
reflect
better
exposur
ebovgp
epitop
remov
part
carbohydr
cloak
vector
also
elicit
robust
ebovgpspecif
igg
respons
contrast
undetect
ebovgpspecif
cellmedi
immun
respons
induc
vector
explan
anomali
unclear
could
due
rel
differ
ebovgpspecif
cellular
humor
antigen
believ
approxim
attenu
express
across
gene
junction
could
drop
ebovgp
level
threshold
requir
elicit
cellmedi
immun
respons
ebovgp
level
still
adequ
induc
rel
robust
humor
respons
howev
ebovgpspecif
humor
respons
declin
markedli
presum
result
calcul
reduct
ebovgp
express
sixth
posit
genom
previou
work
demonstr
vector
backbon
highli
attenu
mous
intracrani
nv
model
howev
western
blot
data
demonstr
ebovgp
present
surfac
viru
particl
express
rvsv
vector
retain
vsv
g
gene
unpublish
data
therefor
mous
nv
studi
perform
assess
chang
virul
aris
possibl
alter
vector
tropism
mediat
ebovgp
result
confirm
highli
attenu
natur
mous
central
nervou
system
indic
presenc
ebovgp
virion
surfac
addit
vsv
g
protein
enhanc
viru
spread
brain
presum
cell
central
nervou
system
lack
ebovgpspecif
receptor
viru
use
vsv
g
receptor
remain
attenu
previous
describ
elicit
desir
balanc
humor
cellular
immun
respons
ebovgp
singl
vaccin
dose
mice
select
guinea
pig
nhp
challeng
studi
one
dose
vector
protect
guinea
pig
sign
diseas
follow
challeng
lethal
dose
gpaebov
interestingli
slight
delay
onset
first
sign
diseas
challeng
wtvsvvaccin
guinea
pig
one
possibl
explan
induct
ifn
innat
immun
respons
rvsv
leav
guinea
pig
innat
immun
system
high
alert
even
day
vaccin
result
gener
antivir
state
may
initi
slow
gpaebov
infect
singl
dose
vector
also
protect
nhp
diseas
follow
ebov
challeng
ebovgpspecif
igg
titer
detect
immun
macaqu
prior
challeng
expand
follow
ebov
challeng
indic
preexist
ebovgpspecif
antibodi
respons
import
protect
unfortun
cellmedi
immun
respons
nhp
measur
may
also
contribut
significantli
protect
vector
use
challeng
studi
similar
highli
attenu
vector
demonstr
safeti
immunogen
phase
clinic
studi
studi
describ
first
demonstr
protect
guinea
pig
macaqu
singl
dose
highli
attenu
rvsv
express
ebovgp
believ
vector
essenti
safeti
efficaci
characterist
use
vaccin
prevent
ebov
infect
human
great
ape
highli
attenu
vector
platform
like
also
potenti
serv
vaccin
ebov
strain
caus
diseas
human
ape
ultim
multival
ebov
vaccin
may
possibl
combin
vaccin
vector
singl
vaccin
formul
